3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
104
Colorectal Neoplasms
63
Stomach Neoplasms
49
Rectal Neoplasms
42
Colonic Neoplasms
24
Neoplasm Metastasis
21
Nasopharyngeal Carcinoma
19
Triple Negative Breast Neoplasms
18
Pancreatic Neoplasms
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
12
Neoplasms
12
Gallbladder Neoplasms
7
Cholangiocarcinoma
7
Adenocarcinoma
6
Esophageal Neoplasms
5
Biliary Tract Neoplasms
5
Adenocarcinoma Of Esophagus
5
Esophageal Squamous Cell Carcinoma
4
Neuroendocrine Tumors
3
Gastrointestinal Neoplasms
3
Digestive System Neoplasms
3
Bile Duct Neoplasms
3
Recurrence
2
Pathologic Complete Response
2
Liver Neoplasms
2
Intestinal Neoplasms
2
Hand-Foot Syndrome
2
HER2-positive Advanced Breast Cancer
2
HER2 Positive Metastatic Breast Cancer
2
Drug-Related Side Effects and Adverse Reactions
2
Interventions
Radiotherapy
8
Cisplatin
3
Carboplatin
3
sargramostim
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Donepezil
2
cevimeline
1
beta Carotene
1
alpha-Tocopherol
1
Zinc Sulfate
1
Vortioxetine
1
Vitamin E
1
Standard of Care
1
Sodium Chloride
1
Salts
1
Radiotherapy, Conformal
1
Radiosurgery
1
Oxygen
1
Oxaliplatin
1
Neck Dissection
1
Mometasone Furoate
1
Meditation
1
Hyperbaric Oxygenation
1
Glutamine
1
G(M1) Ganglioside
1
Filgrastim
1
Fibroblast Growth Factor 7
1
Etoposide
1
Erythropoietin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Radiation Injuries
×
Capecitabine
×
Clear all
NCT02121405
2022-05-11
PSSR
Zhejiang University
Phase 3
Suspended
350 enrolled